Intellia Therapeutics CFO sells 8,111 shares
Intellia Therapeutics EVP and CFO Edward J. Dulac III reported a mandatory sell-to-cover sale of 8,111 shares of common stock on July 22, 2026 to satisfy tax withholding from RSU vesting.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Intellia Therapeutics EVP and CFO Edward J. Dulac III reported a mandatory sell-to-cover sale of 8,111 shares of common stock on July 22, 2026 to satisfy tax withholding from RSU vesting. The shares were sold at a weighted average price of $11.25, within a range from $11.25 to $11.28, leaving 148,175 shares directly owned.
Insider Trade Summary
Net Seller: 8,111 shares
Net Sell
1 txn
Insider
Dulac Edward J III
Role
EVP, Chief Financial Officer
Sold
8,111 shs ($91K)
Share of Position Sold
5.2%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 8,111 | $11.25 | $91K |
Holdings After Transaction:
Common Stock — 148,175 shares (Direct)
Holdings Before and After:
Common Stock, 156,286 to 148,175 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (2)
- F1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price.
Key Figures
Shares sold: 8,111 shares
Weighted average sale price: $11.25 per share
Sale price range: $11.25 to $11.28
+1 more
4 metrics
Shares sold
8,111 shares
Mandatory sell-to-cover transaction on July 22, 2026 to satisfy tax withholding from RSU vesting
Weighted average sale price
$11.25 per share
Weighted average price for 8,111 shares sold in multiple transactions
Sale price range
$11.25 to $11.28
Range of prices at which the 8,111 shares were sold on July 22, 2026
Shares owned after transaction
148,175 shares
Directly owned common stock following the July 22, 2026 sell-to-cover transaction
Key Terms
sell-to-cover, weighted average price, RSUs
3 terms
sell-to-cover financial
"Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying tax"
Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
RSUs financial
"tax withholding obligation upon the vesting of RSUs on July 22, 2026"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did NTLA’s CFO report on July 22, 2026?
EVP and CFO Edward J. Dulac III reported a sale of 8,111 shares of Intellia Therapeutics common stock on July 22, 2026. This was a mandatory sell-to-cover transaction to satisfy tax withholding from RSU vesting, not a discretionary trade.
Was the NTLA CFO’s July 22, 2026 stock sale a discretionary trade?
No. The filing states the sale was a mandatory “sell-to-cover” to meet tax withholding obligations from RSU vesting. It explicitly notes this sale “does not represent a volitional trade” by the reporting person, distinguishing it from elective open-market selling.
What does “sell-to-cover” mean in the NTLA CFO’s Form 4?
In this context, “sell-to-cover” means the company sold 8,111 shares on the CFO’s behalf to cover tax withholding from vested RSUs. The footnote clarifies this transaction was mandatory for taxes and not a voluntary investment decision by the CFO.
AI-generated analysis. How Rhea-AI works. Not financial advice.
